Addressing the Challenges of Alzheimer’s Agitation
Advancing IGC-AD1 in the CALMA trial—supporting patients and caregivers through science and compassion.
How is
IGC Pharma
fighting agitation?
IGC Pharma is advancing IGC-AD1, a cannabinoid-based investigational therapy in a double-blind Phase 2 trial (CALMA), designed to reduce agitation and improve quality of life.
Our Science, Our Commitment
What is CALMA?
CALMA is a multicenter Phase 2 clinical trial designed to evaluate the safety and potential efficacy of IGC-AD1 for treating agitation in participants with dementia due to Alzheimer's disease.
Explore CALMA →What is IGC-AD1?
IGC-AD1 is IGC Pharma’s lead candidate—a partial CB1 receptor agonist with anti-inflammatory action, designed to address agitation associated with Alzheimer’s disease.
Learn About IGC‑AD1 →What is MINT-AD?
MINT-AD is IGC Pharma’s AI-powered platform that leverages multimodal data to support early Alzheimer’s detection and improve understanding of disease progression.
Discover MINT‑AD →What is TGR-63?
A small molecule designed to inhibit amyloid plaque aggregation in neuronal tissue, with the ability to cross the blood–brain barrier and demonstrated pre-clinical behavioral efficacy.
Learn About TGR-63 →Latest Press Releases
Explore how IGC Pharma’s data, trials, and milestones are shaping a brighter future for Alzheimer’s care.
IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer’s Data Harmonization Time by 90% in Representative Workflow
IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company
IGC Pharma’s AHA Agentic AI Platform Reduces Alzheimer’s Data Harmonization Time by 90% in Representative Workflow
IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis
Together, we’re turning research into resilience, and innovation into care for millions worldwide.
Americans projected to have Alzheimer’s disease by 2043
Americans projected to have Alzheimer’s disease by 2060
Leading cause of death among Americans aged 65+
Expected cost of Alzheimer’s and dementia by 2050 (in 2024 dollars) if no treatment or cure is found.
Pipeline
IGC Pharma’s pipeline bridges breakthroughs from AI-enhanced
early detection to IGC-AD1 and beyond, advancing Alzheimer’s
treatment frontiers.
In-depth insights,
real impact
“Science Spotlight” reveals our latest Alzheimer’s research, breakthroughs, and care innovations.
Investing in the Future:
IGC Pharma stands with families and vulnerable groups, investing in research, education, advocacy and Alzheimer’s awareness.
